Location of Repository

Cardiovascular tests: use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disorders

By Caroline L. Smith and Patrick Vallance

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenously occurring methylarginine that inhibits nitric oxide synthesis. Plasma levels of methylarginines increase in renal failure and certain cardiovascular pathologies, and in patients with end stage renal failure the level of ADMA predicts the risk of cardiovascular events and overall mortality. The object of this review is to describe the mechanisms of ADMA synthesis, metabolism and uptake and to outline techniques for measuring ADMA and the pathological states in which ADMA levels are altered

Topics: UOW2
OAI identifier: oai:westminsterresearch.wmin.ac.uk:1681
Provided by: WestminsterResearch

Suggested articles

Preview

Citations

  1. (2001). Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int.
  2. (1999). Cationic amino acid transporter gene expression in cultured vascular smooth muscle cells and in rats.
  3. (1993). Characterization of endothelial cell amino acid transport systems involved in the actions of nitric oxide synthase inhibitors. Mol Pharmacol.
  4. (1998). Characterization of L-arginine uptake by plasma membrane vesicles isolated from cultured pulmonary artery endothelial cells. Biochim Biophys Acta.
  5. (1996). Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant.
  6. (2002). Cooke JP et a.l Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism.
  7. (2002). Cooke JP.Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.Circulation.
  8. (2002). Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem.
  9. (2001). Dialysis improves endothelial function in humans.Nephrol Dial Transplant.
  10. (2001). Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond).
  11. (2002). Endogenous methylarginines regulate neuronal nitric-oxide synthase and prevent excitotoxic injury.
  12. (1999). Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation.
  13. (2003). Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet.
  14. (2003). Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation.
  15. (2003). Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation.
  16. (1998). Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int.
  17. (2001). Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation.
  18. (1997). Imaizumi T.Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension.
  19. (1995). Induction of L-arginine transport and nitric oxide synthase in vascular smooth muscle cells: synergistic actions of pro-inflammatory cytokines and bacterial lipopolysaccharide.
  20. (1995). Induction of NG-monomethyl-Larginine uptake: a mechanism for differential inhibition of NO synthases? A m
  21. (2002). Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int.
  22. (1992). Mann GE.Identification of inhibitors of nitric oxide synthase that do not interact with the endothelial cell L-arginine transporter.Br
  23. (2003). Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation.
  24. (1996). Nitric oxide exposure and sulfhydryl modulation alter Larginine transport in cultured pulmonary artery endothelial cells. Free Radic Biol Med.
  25. (1998). Nussey SS.Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol.
  26. (2003). O et al Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism.
  27. (1970). Omega-N-methylarginine in protein.
  28. (2001). Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet.
  29. (1993). Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy
  30. (2001). Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol.
  31. (1999). Regulation of macrophage nitric oxide synthesis by endothelial cells: a role for NG,NG-dimethylarginine. Acta Physiol Scand.
  32. (2002). Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA.
  33. (1990). Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells.Biochem Biophys Res Commun.
  34. (2001). Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol Renal Physiol.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.